Refine by
Allogeneic Cell Equipment & Supplies
59 equipment items found
Manufactured by:DiscGenics, Inc. based inSalt Lake City, UTAH (USA)
DiscGenics uses its patented allogeneic cell culture manufacturing technology to isolate cells from donated adult human intervertebral disc tissue and induce a progenitor state. These proprietary Discogenic Cells are then expanded for therapeutic application, combined with a delivery vehicle and cryopreserved for off-the-shelf ...
by:Scinogy Pty Ltd based inVictoria, AUSTRALIA
Scinogy's allogeneic cell processing systems are uniquely configured to realize economies of scale and optimize facility, equipment and staff utilization. These automated and integrated systems are designed to consistently processes multiple batches on any given day. Closed, single use kits enable parallel processing of multiple batches in a common, lower ...
Manufactured by:healiva SA based inLugano, SWITZERLAND
Our scalable treatment for chronic leg ulcers that are not responding to standard of care, using automated ...
by:ABEC, INC. based inBethlehem, PENNSYLVANIA (USA)
Our conditionally-immortalized allogeneic cell lines are derived from hematopoietic stem cells and allows us to eliminate the need for recurring donors. From a single cell line, we can produce unlimited quantities of consistent fully-functional cells with targeted ...
Manufactured by:Stemedica Cell Technologies, Inc. based inSan Diego, CALIFORNIA (USA)
There are two types of cells currently used for investigating progenitor cell therapies for degenerative diseases: autologous and allogeneic. Autologous progenitor cells are derived from the patient being treated. They are retrieved surgically, expanded, and transplanted back into the same patient. Allogeneic ...
Manufactured by:Alphageneron based inCambridge, MASSACHUSETTS (USA)
An allogenic NK cell therapy that targets tumors expressing mHsp70. Patients are selected with high mHsp70 exosomes in their blood using our Companion Diagnostic AP-CDx (described below). We obtain PBMCs from healthy donors by apheresis, their NK cells are expanded, and incubated ex vivo with TKD and IL-2, followed by freezing, thawing and ...
Manufactured by:Nkarta, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Cell therapy, a new approach that uses immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. First generation approaches have focused on T-cells, which have shown great promise in hematologic malignancies but are plagued with unwanted side effects and, to date, have not shown similar activity in solid tumors. Nkarta was founded to address these ...
Manufactured by:Tevogen Bio based in, NEW JERSEY (USA)
Innovative Science in Virology, Oncology, and Neurology; Allogeneic CD8+ T cell therapies from a single donor to treat thousands for the first ...
Manufactured by:MitoImmune Therapeutics Inc. based inGangnam-gu, SOUTH KOREA
MIT-001 is an innovative clinical candidate that blocks the root cause of graft-versus-host disease, which often occurs during allogenic hematopoietic stem cell transplantation (HSCT), through a mechanism of action that is differentiated from any current ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
VCAR33ALLO uses allogeneic healthy donor-derived cells. There has been an increasing appreciation for the value of cell phenotype in CAR-T approaches, and HLA-matched healthy donor cells are a potentially superior cell phenotype with improved persistence and in vivo expansion ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 3301 (Undisclosed CAR NK) will be developed on the next generation CORE-NK platform leveraging a currently undisclosed Chimeric Antigen ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 2301 (CDH17 CAR NK) will be developed on the next generation CORE-NK platform leveraging our CDH17 Chimeric Antigen ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 1301 (CLTX CAR NK) will be developed on the next generation CORE-NK platform leveraging our CLTX Chimeric Antigen ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
The product profile of SENTI-301 has the potential to promote expansion and persistence of NK cells, and activate and recruit the body’s own immune cells into the solid tumor microenvironment for enhanced anti-tumor activity. ...
by:The Regeneration Center based inBangkok, THAILAND
Cord blood refers to blood left in the umbilical cord after birth. Back in the day, this was generally discarded. However, because of modern advances in regenerative medical sciences, scientists have found a very useful purpose for them. The goal now is preservation or application of cord blood instead of discarding them. Why? Because it has been found to be rich in mesenchymal stem ...
by:The Regeneration Center based inBangkok, THAILAND
Several clinical studies have clearly demonstrated the benefits of stem cells. Peer-reviewed medical journals today are intent on finding the richest source of stem cells in the human body. Researchers have found that umbilical cord blood is rich in stem cells, which eventually paved the way for researchers to move away from the controversial embryonic stem cells. As a result of these trials, it ...
by:The Regeneration Center based inBangkok, THAILAND
Dental pulp stem cells derived (DPSCs) represents a new and exciting alternative source of adult stem cells for use in regenerative medicine. The DPSCs are considered very unique because the cells are relatively easy acquire in an extremely safe and low invasive procedures. During our early development, dental pulp is the main source of nutrition of our jaw,brain and developing teeth due to them ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
The next generation CORE-NK platform will integrate additional activation and expansion features to further optimize the cancer-fighting power of the CORE-NK platform cells. Development of the next generation CORE-NK platform will be as a combination therapy for blood ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
The CORE-NK platform is a transformative platform technology for Chimeric enabling the accelerated development of multiple next generation, off the shelf NK and CAR-NK products. Natural killer cells are found in our bodies naturally and are able to recognize and kill cancer cells – but are not robust and active enough to overcome cancer as it grows. CORE-NK platform cells are made by ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
TC BioPharm’s cell banks have been developed as a resource for clinical development of cost-effective, safe and efficacious therapeutic treatments and ultimately, the ability to treat more patients. These T cell banks provide TC BioPharm with core technology to develop a deep portfolio of next-generation CAR-T products directed against a wide variety of different infectious diseases such as ...